Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Excretion of [14C] Mezigdomide in Healthy Males
NCT04560738Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of mezigdomide in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoints: Cumulative excretion of [14C]-RA, Time to Maximum Concentration (Tmax) and 7 more. Started Oct 2020; status: completed.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04560738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04560738.